Cargando…

CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia

Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system' that could facilitate the screening of new therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Pasquale, E, Lodola, F, Miragoli, M, Denegri, M, Avelino-Cruz, J E, Buonocore, M, Nakahama, H, Portararo, P, Bloise, R, Napolitano, C, Condorelli, G, Priori, S G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824678/
https://www.ncbi.nlm.nih.gov/pubmed/24113177
http://dx.doi.org/10.1038/cddis.2013.369
_version_ 1782290729063677952
author Di Pasquale, E
Lodola, F
Miragoli, M
Denegri, M
Avelino-Cruz, J E
Buonocore, M
Nakahama, H
Portararo, P
Bloise, R
Napolitano, C
Condorelli, G
Priori, S G
author_facet Di Pasquale, E
Lodola, F
Miragoli, M
Denegri, M
Avelino-Cruz, J E
Buonocore, M
Nakahama, H
Portararo, P
Bloise, R
Napolitano, C
Condorelli, G
Priori, S G
author_sort Di Pasquale, E
collection PubMed
description Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system' that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after β-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca(2+)/calmodulin-dependent serine–threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies.
format Online
Article
Text
id pubmed-3824678
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38246782013-11-12 CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia Di Pasquale, E Lodola, F Miragoli, M Denegri, M Avelino-Cruz, J E Buonocore, M Nakahama, H Portararo, P Bloise, R Napolitano, C Condorelli, G Priori, S G Cell Death Dis Original Article Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system' that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after β-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca(2+)/calmodulin-dependent serine–threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies. Nature Publishing Group 2013-10 2013-10-10 /pmc/articles/PMC3824678/ /pubmed/24113177 http://dx.doi.org/10.1038/cddis.2013.369 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Di Pasquale, E
Lodola, F
Miragoli, M
Denegri, M
Avelino-Cruz, J E
Buonocore, M
Nakahama, H
Portararo, P
Bloise, R
Napolitano, C
Condorelli, G
Priori, S G
CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
title CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
title_full CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
title_fullStr CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
title_full_unstemmed CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
title_short CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
title_sort camkii inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824678/
https://www.ncbi.nlm.nih.gov/pubmed/24113177
http://dx.doi.org/10.1038/cddis.2013.369
work_keys_str_mv AT dipasqualee camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT lodolaf camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT miragolim camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT denegrim camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT avelinocruzje camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT buonocorem camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT nakahamah camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT portararop camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT bloiser camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT napolitanoc camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT condorellig camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia
AT priorisg camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia